Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 16/20 | 0.57 |
| ▸ | PPID | Q08752 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 9/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 4/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.50 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10456811 | 0.89 | PPID (0.56) | PPID | |
| SCHEMBL4416626 | 0.88 | PPID (0.55) | PPID | |
| SCHEMBL7386068 | 0.84 | ITGB3 (0.57) | F7F2ITGB3ITGA2B | |
| SCHEMBL16166399 | 0.83 | POLB (0.56) | F7F2ITGB3ITGA2BF10 | |
| SCHEMBL10192183 | 0.83 | PPID (0.62) | PPID | |
| SCHEMBL13714709 | 0.81 | F2 (0.61) | F7F2ITGB3ITGA2BF10 | |
| SCHEMBL13714617 | 0.81 | F7 (0.65) | F7F2F10 | |
| SCHEMBL5181438 | 0.80 | PPID (0.59) | PPID | |
| SCHEMBL10458688 | 0.80 | PPID (0.56) | PPID | |
| SCHEMBL10458690 | 0.80 | PPID (0.56) | PPID |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299354-B1 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISH HEALTHCARE AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISH HEALTHCARE AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-6743790-B2 | A UREA OR THIOUREA DERIVATIVES CONTAINING AMIDE GROUP USEFUL AS ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| EP-1299354-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | Aventis Pharma Deutschland GmbH (DE) | 2003-04-09 | — | — | EP | disclosed |
| US-20020052417-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-05-02 | — | — | US | disclosed |
| WO-2001094301-A2 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-12-13 | — | — | WO | disclosed |
| EP-1162194-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | Aventis Pharma Deutschland GmbH (DE) | 2001-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | F7, F5, F8 | F7 1/4885PPID 417/4885F2 9/4885 |
| US-20020052417-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | F7, F9, F5 | F7 1/4885PPID 2134/4885F2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.